Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Hold" from Analysts
Market Beat·- Nuvalent, Inc. has received an average recommendation of "Hold" from twenty research firms, with one sell, fifteen hold, and four buy ratings. - The average twelve-month price target among analysts is $127.73, with recent downgrades affecting price targets to around $124.00. - The company specializes in targeted therapies for genetically defined cancers and reported a loss of $1.39 EPS, below the expected $1.35 EPS.